Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older
Methods| This population-based study used the French National Health Data System linked
to the national COVID-19 vaccination database. Eligible participants were all persons …
to the national COVID-19 vaccination database. Eligible participants were all persons …
Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France
J Botton, MJ Jabagi, M Bertrand, B Baricault… - Annals of internal …, 2022 - acpjournals.org
Background: The BNT162b2 (Pfizer–BioNTech) vaccine has been shown to be safe with
regard to risk for severe cardiovascular events (such as myocardial infarction [MI] …
regard to risk for severe cardiovascular events (such as myocardial infarction [MI] …
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case …
Background COVID-19 continues to be a major health threat, particularly among at-risk
groups, including individuals aged 60 years or older and people with particular medical …
groups, including individuals aged 60 years or older and people with particular medical …
Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England
TFD Mason, M Whitston, J Hodgson, RE Watkinson… - BMC medicine, 2021 - Springer
Abstract Background The BNT162b2 mRNA vaccine has been shown to be effective at
preventing serious COVID-19 events in clinical trials. There is less evidence on …
preventing serious COVID-19 events in clinical trials. There is less evidence on …
Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
Background Preapproval trials showed that messenger RNA (mRNA)–based vaccines
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety …
Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study
Background This study aims to evaluate the association between thromboembolic events
and hemorrhagic stroke following BNT162b2 and CoronaVac vaccination. Methods Patients …
and hemorrhagic stroke following BNT162b2 and CoronaVac vaccination. Methods Patients …
Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries
JD Berild, VB Larsen, EM Thiesson… - JAMA network …, 2022 - jamanetwork.com
Importance Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are
essential to determine the risk-benefit ratio of each COVID-19 vaccine. Objective To …
essential to determine the risk-benefit ratio of each COVID-19 vaccine. Objective To …
The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort …
A Glatman-Freedman, M Bromberg, R Dichtiar… - …, 2021 - thelancet.com
Background The rapid vaccination campaign against COVID-19 in Israel relied on the
BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using …
BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using …
[HTML][HTML] Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
Background The effectiveness of the second BNT162b2 (Pfizer–BioNTech) mRNA COVID-
19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to …
19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to …
[HTML][HTML] Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines
Background Canadian and international data suggest the risk of myocarditis and/or
pericarditis is elevated during the week after mRNA COVID-19 vaccination, particularly in …
pericarditis is elevated during the week after mRNA COVID-19 vaccination, particularly in …